Incanthera plc

AGM Information • Oct 6, 2025

National Storage Mechanism | Additional information

RNS Number : 1685C

Incanthera PLC

06 October 2025

6 October 2025

Incanthera plc

("Incanthera" or the "Company")

INVESTOR PRESENTATION

PROACTIVE BIOTECH ONE2ONE INVESTOR FORUM

9 OCTOBER 2025

Incanthera plc   (AQSE:INC), the   company specially focussed on innovative technologies in dermatology and oncology, announces that it will be presenting at the Proactive Investor Forum in London at 6.00 p.m. on Thursday 9 October 2025 to an audience of high net worth investors, fund managers, private client brokers and analysts.

Incanthera will be delivering a presentation, which will not contain any inside information, and will be made available on its website,   www.incanthera.com .

In order to register for the event, please use the attached link:  Proactive One2One Investor Forum - Thursday 9th October Tickets, Thu 9 Oct 2025 at 18:00 | Eventbrite

RNS Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature.

For further information please contact:

Incanthera plc:                                                                                                                                                                   

www.incanthera.com Tim McCarthy, Chairman [email protected] Simon Ward, Chief Executive Officer [email protected] Suzanne Brocks, Head of Communications [email protected]	+44 (0) 7831 675747 +44 (0) 7747 625506 +44 (0) 7776 234600
Broker:  Stanford Capital Partners Ltd Patrick Claridge / Bob Pountney	+44 (0) 20 3650/51

Notes to Editors

Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford.  Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit:  www.incanthera.com

@incantheraplc

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRALELLBEBLZFBB